Key Takeaways
- Strong FY26, momentum in H2: Revenue reached INR518 crores with H2 contributing ~INR302 crores, while EBITDA margins sharpened to ~13% in the second half on better product mix and operating leverage.
- Order book provides multi-year visibility: Order inflows of ~INR960 crores pushed the order book to INR1,309 crores, with defense contributing 85–90% of the backlog.
- Strategic moves signal ambition: A preferential equity raise of INR150 crores, a new JV with an Israeli defense prime, a US subsidiary, and Nadcap accreditation all landed this year, laying groundwork for the next phase.
- Margins guided lower for FY27: Despite H2's ~13% run-rate, management guided FY27 EBITDA margins to 11–12% as investments in capacity and qualification cycles weigh before operating leverage returns.
- What to watch next quarter: Whether the 25–30% order inflow growth target materializes, progress on the Israeli JV disclosure, and any update on the two US programs that drove subsidiary incorporation.
Order Book & Revenue Visibility
- Defense anchors the backlog: 85% to 90% of the INR1,309-crore order book sits in defense, with long-term purchase orders providing multi-year visibility; aerospace, industrial, and transportation segments run on rolling forecasts.
- Order inflow growth targeted at 25–30%: Management expects FY27 inflows to exceed FY26's ~INR960 crores by a quarter to a third, with large purchase orders weighted toward H2.
- Growth momentum seen as durable: Management confirmed that the 30–35% growth trajectory can be sustained beyond FY27, supported by the order book and capacity expansion underway.
- Exports crossed a threshold: FY26 saw exports approach 50% of revenue, a milestone management expects to hold in a roughly 50/50 range going forward.
Sumukh Narendra: "Over the last two and a half decades, we have grown from a focused electronics manufacturing business into a trusted manufacturing partner serving some of the most demanding and highly regulated industries."
Capacity Expansion & Utilization
- INR30 crores capex nearing completion: The new 25,000-square-foot facility focused on Class 3 integration and system-intensive programs is expected to be available in two to three months from the call date, around August 2026.
- Qualification cycle dictates revenue conversion: On the aerospace and defense side, new lines must undergo customer qualification after infrastructure installation, a process management has already initiated so that capacity and approvals align for smooth execution.
- Utilization intentionally capped: Current utilization sits at 35–40% post-expansion, and management does not intend to reach peak utilization on the defense and aerospace side because of the high-mix, low-volume nature of the work.
- Growth absorbs capacity gradually: With 25–30% year-on-year growth targeted, the capacity headroom is designed to accommodate multiple years of expansion without a near-term ceiling.
Sumukh Narendra: "On the aerospace and defense side, we have a long gestation period for qualification of the lines. So post the installation of the infrastructure, we need to qualify those, qualify the infrastructure with our customers as well. Keeping that in mind, we have started the process and we feel that by the time the qualification is completed, the capex will be in place to ensure that we are able to have smooth execution of the orders."
Strategic Initiatives: JV, US Subsidiary & New Verticals
- Israeli defense JV signals tier-1 trust: Vinyas signed a joint venture agreement with a leading Israeli defense prime for manufacturing defense systems in India, though management declined to share details, calling it too early.
- US subsidiary targets two live programs: A wholly owned subsidiary has been incorporated in the US after Vinyas was shortlisted for two manufacturing programs there; initial setup is underway and both opportunities are being actively pursued.
- Medical segment adds diversification: A new healthcare customer was onboarded, with manufacturing expected to ramp up by the end of the calendar year; management is targeting roughly 5% of FY27 revenue from the medical side.
- Nadcap accreditation raises the quality bar: Achieving Nadcap for electronic and PCB assemblies positions Vinyas among a small set of manufacturers qualified for the most demanding aerospace and defense process standards.
Sumukh Narendra: "We recently joined a joint venture agreement with a leading Israeli defense company and we believe this partnership represents an important milestone in our evolution and reflects the confidence that global defense companies place in India's manufacturing ecosystem and in Vinyas' capabilities."
Margin Dynamics & Product Mix
- H2 margins benefited from mix, not just scale: EBITDA margins of ~13% in H2 were driven by the product mix executed in the second half, with more system integration work lifting profitability alongside operating leverage.
- FY27 guidance embeds investment drag: Management guided FY27 EBITDA margins to 11–12%, below the H2 FY26 run-rate, as capacity expansion costs and qualification cycles weigh before the new infrastructure contributes.
- System integration shift is the margin lever: As product mix improves with a greater share of system integration programs, margins are expected to inch up over time, though the pace depends on order composition.
- Defense pricing offers input-cost protection: On the defense side, Vinyas is protected in terms of input raw material pricing, insulating a large portion of the business from near-term supply-chain volatility.
Supply Chain & Risk
- Semiconductor and logistics pressures are easing: Short-term challenges in semiconductor availability and logistics have abated over the last three to four weeks, with further improvement expected over the next three to four months.
- Israel dependency is manageable at 10–15%: Supply chains from Israel were briefly disrupted during geopolitical tensions but have since smoothened out with better logistics channels to India.
- Defense backlog provides a buffer: Because the defense order book is long-cycle and pricing-protected, near-term input-cost swings have a muted impact on the majority of revenue.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| EBITDA margin | 11% to 12% for FY27 | FY27 full year |
| Order inflow growth | 25% to 30% above FY26 (~INR960 crores) | FY27, with large POs in H2 |
| Revenue growth momentum | 30% to 35% sustained growth | Beyond FY27 |
| New capacity available | INR30 crores capex yielding 25,000 sq ft | Two to three months from call date (~Aug 2026) |
| Medical revenue contribution | ~5% of FY27 revenue | FY27 |
| Export revenue share | Roughly 50/50 domestic/export | Going forward |
Key Metrics
| Metric | FY26 |
|---|---|
| Revenue | ₹518 cr |
| H2 Revenue | ~₹302 cr |
| EBITDA | ₹64.77 cr |
| EBITDA margin | 12.5% |
| Profit after tax | ₹30.87 cr |
| Order inflows | ~₹960 cr |
| Order book (as of 31 Mar 2026) | ₹1,309 cr, defense 85–90% |
| Order book execution timeline | 18–24 months |
| Capacity utilization (post expansion) | 35–40% |
| Peak revenue capacity (post expansion) | ₹2,000–2,100 cr |
| Exports share of revenue | ~50% |
| FY27 revenue growth outlook | 25–30% year-on-year |
| FY27 EBITDA margin guidance | 11–12% |
| FY27 order inflow growth expectation | 25–30% over FY26 |
| FY27 medical revenue target | ~5% of total revenue |